Avantor Investor Day Presentation Deck slide image

Avantor Investor Day Presentation Deck

Emerging technologies augment healthcare growth opportunity MEDICAL IMPLANTS IMPLANTABLE MEDICAL DEVICES CAGR >6% EMERGING NOVEL MEDICAL & DIAGNOSTIC TECHNOLOGIES Novel Wearable Drug Delivery NuSil medical-grade silicone CAGR >20% Management Estimates. CAGRs represent estimated revenue growth from 2023 to 2028. 1. Noninvasive oncology screening references specific indications, such as colon cancer screening. Surgical Robots AVTR lubricious silicones CAGR >10% 3D-Printed Medical Devices NuSil medical-grade silicone 3 CAGR >15% HEALTHCARE Noninvasive Oncology Screening¹ AVTR custom reagents CAGR >10% Navantor™ 65
View entire presentation